Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients

Altundag K., Silay Y., Altundag O., Yigitbasi O., Gundeslioglu O., Gunduz M.

MEDICAL HYPOTHESES, vol.64, no.6, pp.1162-1165, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 64 Issue: 6
  • Publication Date: 2005
  • Doi Number: 10.1016/j.mehy.2004.11.041
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1162-1165
  • Hacettepe University Affiliated: No


Recently, cyclooxygenase-2 (COX-2) inhibitor therapy has emerged as a possible new approach to the prevention and treatment of cotorectal cancer (CRC). The COX enzymes (COX-1 and COX-2) are key enzymes of prostaglandin (PG) biosynthesis and are overexpressed in approximate to 80% of human CRCs. Presumably, bioactive lipid products of COX, such as PGE(2), are responsible for some of the pro-neoplastic effects mediated by this enzyme. The early effects of COX-2-derived PGE2 are in part mediated by the epidermal growth factor receptor (EGFR). Selenomethionine decreases COX-2 protein and PGE(2). levels. Cetuximab is a chimeric IgG1 monoclonal antibody that binds to EGFR with high specificity thus blocking ligand-induced phosphorytation of EGFR. Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory CRC. We suggest that selenium supplementation by decreasing the COX-2 protein and PGE-2 Levels in cancer cells may increase efficacy of cetuximab in advanced CRC patients. (c) 2004 Elsevier Ltd. All rights reserved.